Cargando…
Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
BACKGROUND: Rituximab is safe and effective for treating relapsing–remitting multiple sclerosis (RRMS) according to phase II and observational studies. There are limited data on disease activity after discontinuation and dose reduction. The objective of this study was to evaluate the effects on infl...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818716/ https://www.ncbi.nlm.nih.gov/pubmed/33475825 http://dx.doi.org/10.1007/s00415-021-10399-8 |